IL17A and psoriasis: In the adults group, there was no significant difference in the rate of SARS-CoV-2 infection (RR: 0.97; 95% CI: 0.62-1.49; P = 0.87) between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics.